<DOC>
	<DOCNO>NCT01956630</DOCNO>
	<brief_summary>Allogeneic hematopoietic cell transplantation ( Allo-HSCT ) currently effective treatment Acute leukemia ( AL ) . Relapse transplantation , main obstacle patient survival , far treated second transplantation donor leukocyte infusion ( DLI ) , seem high risk low survival . Need new medication relapse urgent . The immunotherapy use Dendritic cell ( DCs ) combine cytokine induce killer ( CIK ) cell hold promise adjuvant treatment AL eradicate control residual disease . This randomized study conduct evaluate feasibility effective genetically modify DCs combine CIK immunotherapy relapse AL allo-HSCT .</brief_summary>
	<brief_title>Clinical Study DC Plus CIK Patients With Relapse Acute Leukemia After Allo-HSCT</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>AL patient accord WHO criterion expect survival duration 3 month age 8 61years underlying autoimmune disease positive serology HIV infection chronic active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>